期刊文献+

HIFU治疗无法手术切除的胰腺癌21例效果观察 被引量:3

Effect of high intensity focused ultrasound on patients with unresectable pancreatic carcinoma
下载PDF
导出
摘要 目的探讨高强度聚焦超声(HIFU)对无法手术切除胰腺癌患者的疗效和安全性。方法将同期收治的36例无法手术切除的胰腺癌患者随机分为治疗组21例和对照组15例,两组均予常规对症支持治疗,在此基础上治疗组采用FEP-BY02型HIFU肿瘤治疗机进行治疗。疗程结束后观察两组临床受益反应(CBR)、肿瘤客观疗效、血清CA19-9水平、生存期、生存率及不良反应发生情况。结果治疗组CBR阳性率、单纯疼痛缓解率、总有效率及12、18个月生存率均显著高于对照组,进展(PD)率、不良反应发生率及血清CA19-9水平均显著低于对照组,生存期显著长于对照组,P<0.05或0.01。结论 HIFU治疗手术无法切除的晚期胰腺癌患者可明显缓解症状、改善生活质量、延长生存期,且安全性高。 Objective To evaluate the effects and safety of HIFU on the patients wi th unresectable pancreatic cancer.Methods Thirty-six cases with unresectable pa ncreatic carcinoma were divided into treatment group(n=21) and control group(n=1 5) randomly.Both groups were given routine supporting therapy,the treatment gro up received HIFU treatment furthermore.When the course of treatment finished,t he clinical benefit reponse(CBR),clinical curative effect,serum level of CA19-9, life span,survival rate and adverse reaction were observed.Results Compared to t he control group,the positive rate of CBR,the remission rate of single pain,the general effective rate and survival rate of 12,18 months increased in the treatm ent group,the rate of PD,the incidence of adverse reaction and serum level of CA 19-9 decreased,the life span prolonged,P0.05 or 0.01.Conclusions HIFU treatmen t can alleviate sufferings,improve life quality and extend life span of patient s with pancreatic carcinoma,and also posses high safety.
机构地区 山东省立医院
出处 《山东医药》 CAS 北大核心 2010年第51期1-3,共3页 Shandong Medical Journal
基金 卫生部医药卫生科技发展研究中心立项课题项目(WKJ2006-1-007)
关键词 高强度聚焦超声 胰腺肿瘤 胰腺癌 high intensity focused ultrasound pancreatic tumor pancreatic carci noma
  • 相关文献

参考文献7

二级参考文献24

  • 1崔进.细胞和组织的损伤、适应与修复[A].宋继谒主编.病理学[C].科学出版社,1999.23~39.
  • 2[1]Rhodes JM. Usefulness of novel timour markers[J]. Ann Oncol,1999,10(Suppl) :4118 - 4121.
  • 3[2]Friess H, Kleeff J,Gumbs A, et al. Molecular versus convertional markers in pancreatic cancer[J]. Digestion, 1997,58:557- 563.
  • 4[3]Olivera JF, Keith R, Jeronme, et al. MUG-1 epithelial tumor mucinbased immunity and cancer vaccines[J]. Immun Rev, 1995,145:61 -83.
  • 5[4]Banfi G,Zerbi A,Pastori S,et al. Behavior of tumor markers GA19-9,CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer[J]. Clin Chem, 1993,39(3) :420 - 423.
  • 6[5]Ritts RE,Pitt HA. Ca19-9 in pancreatic cancer[J]. Surg Oncol Clin N Am, 1998,7:93 - 101.
  • 7[6]Dalgleish AG. Tumour markers in malignancies CAA19-9 is useful in several cancers[J]. BMJ,2000,321(7257) :380.
  • 8Edward L,Bradley E, Peter R. et al. Diagnosis and initial management of blunt pancrearis trauma. Ann Surg, 1998, 227(6): 861 - 869.
  • 9Takishima T, Sugimoto K, Hirata M, et al. Serum anaylase level on admission in the diagnosis of blunt injury to the pancreas. Ann Surg, 1997, 226(1):70- 76.
  • 10Kemppainen E, Sainio V, Kivisaail, et al. Early licalization of necrosis by contrast - enhanced computered tomegraphy can predict outcome in severve acute pancreatitis. Br J Surg, 1996, 83:924 - 929.

共引文献74

同被引文献51

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部